Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study.
Gascon
P
P
Division of Medical Oncology, Hospital Clinic Provincial, Barcelona, Spain.
Pirker
R
R
Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Del Mastro
L
L
Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Durrwell
L
L
Clinical Science-Anemia, Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: laurence.durrwell@roche.com.